Intestinal epithelial Smad7 drives purine metabolic dysregulation and ileal inflammation

Laudisi F
Rome University
February 17, 2026
J Biomed Sci
https://pubmed.ncbi.nlm.nih.gov/41703574/

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/41703574/

Research summary

The study investigates the role of Smad7 overexpression in intestinal epithelial cells. Mice with epithelial-specific Smad7 overexpression developed spontaneous ileal inflammation characterized by epithelial damage, mucus depletion, increased permeability, and CD8 positive T cell infiltration. Altered purine metabolism with reduced CD73 expression led to decreased adenosine levels, and adenosine supplementation restored epithelial function and reduced inflammation.

Key outcome of the study

Smad7 overexpression in epithelial cells induces ileal inflammation through impaired purine metabolism and reduced adenosine production. Restoration of adenosine rescues epithelial barrier function and reduces inflammation.

Model

Smad7 overexpression conditional Knockin mouse in intestinal epithelium Smad7TgCre+ model

TARGET:
Smad7
Synonyms:
MADH7, Mothers against decapentaplegic homolog 7

Keywords

Inflammatory bowel disease, Crohn disease, mucosal immunity, epithelial barrier dysfunction, purine metabolism

Technical specifications

Conditional epithelial overexpression of Smad7 using Cre system, spatial transcriptomics, metabolomics analysis, cytokine profiling, histopathology, adenosine rescue experiments

Related products

Catalogue product

No items found.

Customized product

Quick KI mouse

The Rosa26 and Hprt gene loci are well suited for gene over-expression, reduced development time and cost with ready-to-use targeting vectors.

Catalogue product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe